NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia

Leukemia

Volumn 26, Issue 3, 2012, Pages 536-542

  Terwey, T H ^a   Vega Ruiz, A ^a   Hemmati, P G ^a   Martus, P ^a   Dietz, E ^a   Le Coutre, P ^a   Massenkeil, G ^a,b   Dorken B ^a   Arnold, R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Klinik für Anästhesiologie Intensiv Notfall und Schmerzmedizin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; AGED; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; KARNOFSKY PERFORMANCE STATUS; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; NATIONAL HEALTH ORGANIZATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REDUCED INTENSITY CONDITIONING; REGRESSION ANALYSIS; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84858000458     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.230     Document Type: Letter

References (9)

1. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
2. Hemmati PG, Terwey TH, Massenkeil G, le Coutre P, Vuong LG, Neuburger S et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype. Int J Hematol 2010; 91: 436-445.
3. Mohty M, de Lavallade H, El-Cheikh J, Ladaique P, Faucher C, Furst S et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison. Leukemia 2009; 23: 194-196.
4. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762. (Pubitemid 36842003)
5. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312. (Pubitemid 41748028)
6. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577-584. (Pubitemid 351264351)
7. Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia 2010; 24: 1852-1858.
8. Arora M, Nagaraj S, Witte J, DeFor TE, MacMillan M, Burns LJ et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009; 43: 149-153.
9. Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114: 702-708.